Novavax (NASDAQ:NVAX) is a small-cap vaccine company, yet it has a very large long-term potential. The company has a great pipeline that is full of depth, and this pipeline should be able to create substantial value for shareholders as it progresses. Furthermore, the recent attempt to merge with Isconova AB should only help to add more depth to the pipeline. Novavax has some very interesting vaccines.
Novavax recently announced a merger with Isconova, in which Novavax will acquire all of the outstanding shares of Isconova. This merger should help to drive long-term growth, given the fact that the companies pipelines seem to compliment one another's quite nicely. The offer values Isconava at $29.6 million. Isconova's board...
|FREE||SA PRO MEMBERS|
|IDEA GENERATOR||X||Exclusive access to 10 PRO ideas every day|
|INVESTING IDEAS LIBRARY||X||Exclusive access to PRO library of more than 15,000 ideas|
|SECTOR EXPERT NETWORK||X||Exclusive access to all sector experts for direct consultation|
|PERFORMANCE TRACKING||X||Track performance of all PRO stock ideas|
|PROFESSIONAL TOOLS||X||Professional Idea Filters to zero-in based on industry, market cap and more|
|PRO Top long ideas returned 21.7% in 2016**|